Literature DB >> 22221828

Parathyromatosis: a rare yet problematic etiology of recurrent and persistent hyperparathyroidism.

Mirella P Hage1, Ibrahim Salti, Ghada El-Hajj Fuleihan.   

Abstract

Recurrent or persistent hyperparathyroidism is an uncommon yet challenging clinical problem, and parathyromatosis is one of its very rare causes. In this minireview, we review causes of recurrent hyperparathyroidism and all cases of parathyromatosis available in the literature. The clinical course of a case of parathyromatosis with the longest follow-up (1977-2011) is described. Similar cases reported between 1975 and the present are reviewed and analyzed to characterize the clinical presentation, course, and management of this rare condition. Parathyromatosis, which is benign parathyroid tissue seeding, has been detailed in 35 patients in the English literature. The majority were female subjects, with end-stage renal disease, in their fifth to sixth decade of life. In most cases, the diagnosis was made intraoperatively; and the condition was often refractory to surgery. A calcimimetic agent was used in 5 cases with end-stage renal disease; serum calcium and/or parathyroid hormone levels decreased in 4 subjects, but only one was reported to experience increments in bone density. Medical management combining a calcimimetic with a bisphosphonate may therefore be a preferred alternative.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22221828     DOI: 10.1016/j.metabol.2011.11.001

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  12 in total

Review 1.  Persistent and recurrent hyperparathyroidism.

Authors:  Carole Guerin; Nunzia Cinzia Paladino; Aoife Lowery; Fréderic Castinetti; David Taieb; Fréderic Sebag
Journal:  Updates Surg       Date:  2017-04-22

2.  Parathyromatosis or recurrent multiple parathyroid adenomas? A case report.

Authors:  Afshin Mohammadi; Mohammad Ghasemi-Rad
Journal:  Maedica (Buchar)       Date:  2012-01

3.  Recurrent primary hyperparathyroidism due to Type 1 parathyromatosis.

Authors:  Monica Jain; David L Krasne; Frederick R Singer; Armando E Giuliano
Journal:  Endocrine       Date:  2016-10-14       Impact factor: 3.633

Review 4.  Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.

Authors:  Themistoklis Tzotzas; Apostolos Goropoulos; Spyridon Karras; Alexandra Terzaki; Athanasios Siolos; Argyrios Doumas; Thomas Zaramboukas; Stelios Tigas
Journal:  Hormones (Athens)       Date:  2022-01-07       Impact factor: 2.885

5.  Parathyromatosis type 2 detected by 99mTc-MIBI SPECT/CT.

Authors:  Huixiao Cao; Ming Zeng; Haisheng Fang; Lijun Tang; Wei Liu
Journal:  Gland Surg       Date:  2019-12

Review 6.  Parathyromatosis: a very rare cause of recurrent primary hyperparathyroidism - case report and review of the literature.

Authors:  M Haciyanli; S Karaisli; S Gucek Haciyanli; A Atasever; D Arikan Etit; E O Gur; T Acar
Journal:  Ann R Coll Surg Engl       Date:  2019-09-11       Impact factor: 1.891

7.  The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case report.

Authors:  Daisuke Takada; Tatsuo Tsukamoto; Miho Fuse; Shinpei Kada; Motoko Yanagita
Journal:  BMC Nephrol       Date:  2017-10-18       Impact factor: 2.388

8.  PARATHYROMATOSIS: A RARE CASE OF RECURRENT HYPERPARATHYROIDISM LOCALIZED BY FOUR-DIMENSIONAL COMPUTED TOMOGRAPHY.

Authors:  Abraham E Wei; Matthew R Garrett; Ankur Gupta
Journal:  AACE Clin Case Rep       Date:  2019-08-14

9.  Parasitic thyroid nodules: cancer or not?

Authors:  Lauren J Baker; Anthony J Gill; Charles Chan; Betty P C Lin; Bronwyn A Crawford
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-05-01

10.  Parathyromatosis Following Endoscopic Parathyroid Surgery: A Rare Occurrence.

Authors:  Ajay Aggarwal; Roopak Wadhwa; Vivek Aggarwal
Journal:  Indian J Endocrinol Metab       Date:  2017 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.